WO2024127332 - CYTOTOXIC COMPOUNDS
National phase entry:
Publication Number
WO/2024/127332
Publication Date
20.06.2024
International Application No.
PCT/IB2023/062733
International Filing Date
14.12.2023
Title **
[English]
CYTOTOXIC COMPOUNDS
[French]
COMPOSÉS CYTOTOXIQUES
Applicants **
PHEON THERAPEUTICS LTD
Inventors
ANDRIOLLO, Paolo
PROCOPIOU, George
JACKSON, Paul
Priority Data
63/387,426
14.12.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5335 | |
| EPO | Filing, Examination, Granting | 25556 | |
| Japan | Filing, Examination, Granting | 2618 | |
| South Korea | Filing, Examination, Granting | 3015 | |
| USA | Filing, Examination, Granting | 12440 |
Total:
48,964
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides, inter alia, glycosylated compounds and conjugates thereof useful for treating cancer.[French]
La présente divulgation concerne, entre autres, des composés glycosylés et des conjugués de ceux-ci utiles pour le traitement du cancer.